臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"shao y y"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 251-300 / 396 (共8页)
<< < 1 2 3 4 5 6 7 8 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2021-01-28T01:06:30Z	Young patients with colorectal cancer have increased risk of second primary cancers	Liang Y.-H.; Shao Y.-Y.; Chen H.-M.; Lai C.-L.; Lin Z.-Z.; Kuo R.N.; Cheng A.-L.; KUN-HUEI YEH; Lai M.-S.
臺大學術典藏	2021-01-28T01:06:29Z	Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan	Shao Y.-Y.; Hsu C.-H.; KUN-HUEI YEH; Chen H.-M.; Yeh Y.-C.; Lai C.-L.; Lin Z.-Z.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2021-01-28T01:06:27Z	Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study	Chen K.-H.; Shao Y.-Y.; Chen H.-M.; Lin Y.-L.; Lin Z.-Z.; Lai M.-S.; Cheng A.-L.; KUN-HUEI YEH
臺大學術典藏	2021-01-28T01:06:25Z	Irinotecan and oxaliplatin might provide equal benefit as adjuvant chemotherapy for patients with resectable synchronous colon cancer and liver-confined metastases: A nationwide database study	Liang Y.-H.;Shao Y.-Y.;Chen H.-M.;Cheng A.-L.;Lai M.-S.;Kun-Huei Yeh; Liang Y.-H.; Shao Y.-Y.; Chen H.-M.; Cheng A.-L.; Lai M.-S.; KUN-HUEI YEH
臺大學術典藏	2021-01-28T01:06:23Z	Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer	Liang Y.-H.;Wei C.-H.;Hsu W.-H.;Shao Y.-Y.;Lin Y.-C.;Chou P.-C.;Cheng A.-L.;Kun-Huei Yeh; Liang Y.-H.; Wei C.-H.; Hsu W.-H.; Shao Y.-Y.; Lin Y.-C.; Chou P.-C.; Cheng A.-L.; KUN-HUEI YEH
臺大學術典藏	2021-01-28T01:06:19Z	A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma	Yang S.-H.;Shao Y.-Y.;Lin C.-C.;Kuo S.-H.;Cheng A.-L.;Kun-Huei Yeh; Yang S.-H.; Shao Y.-Y.; Lin C.-C.; Kuo S.-H.; Cheng A.-L.; KUN-HUEI YEH
臺大學術典藏	2021	Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan	Tseng J.-H.; Ho M.-C.; Liao L.-Y.; Liang J.-D.; Wang C.-K.; Lee W.-C.; Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Lee R.-C.; Liang P.-C.; Huang K.-W.; Hu J.-T.; Kee K.-M.; Lin C.-L.; Lu S.-N.; Wang J.-H.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; CHIUN HSU; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group
臺大學術典藏	2020-11-27T03:25:51Z	National policies fostering hospice care increased hospice utilization and reduced the invasiveness of end-of-life care for cancer patients	Shao Y.-Y.;Hsiue E.H.-C.;Hsu C.-H.;Chien-An Yao;Chen H.-M.;Lai M.-S.;Cheng A.-L.; Shao Y.-Y.; Hsiue E.H.-C.; Hsu C.-H.; CHIEN-AN YAO; Chen H.-M.; Lai M.-S.; Cheng A.-L.
臺大學術典藏	2020-11-27T03:24:52Z	Emergency department presentation of chronic peritoneal dialysis patients	Pai M.-F.; Hsu S.-P.; Peng Y.-S.; Chiang C.-K.; Ho T.-I.; Shao Y.Y.; Lee H.-Y.; KUAN-YU HUNG
臺大學術典藏	2020-10-07T08:50:38Z	Solving the deficit of cancer pain management skills by education programs	WEN-YING LIN; Shao Y.-Y; Lin C.-P; Lu L.-C; Hsu C.-H.
臺大學術典藏	2020-08-14T03:15:30Z	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma	Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; I-LUN SHIH; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2020-08-12T02:42:37Z	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy	Chao Y.; Hsu C.; Lee R.-C.; Lin Z.-Z.; BANG-BIN CHEN; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lin Z.-Z.;Bang-Bin Chen;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Hsu C.-H.;Cheng A.-L.;Lee R.-C.;Chao Y.;Hsu C.
臺大學術典藏	2020-08-11T08:36:55Z	Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment	Cheng A.-L.; Tien Y.-W.; PO-CHIN LIANG; Shao Y.-Y.; Lin Z.-Z.
臺大學術典藏	2020-08-11T08:36:51Z	A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy	Shao Y.-Y.; PO-CHIN LIANG; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lin Z.-Z.
臺大學術典藏	2020-08-07T02:32:18Z	Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy	Shao Y.-Y.; CHIH-HORNG WU; Lu L.-C.; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2020-07-03T08:45:42Z	Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy	Shao Y.-Y;Chen B.-B;Da-Liang Ou;Lin Z.-Z;Hsu C.-H;Wang M.-J;Cheng A.-L;Hsu C.; Shao Y.-Y; Chen B.-B; DA-LIANG OU; Lin Z.-Z; Hsu C.-H; Wang M.-J; Cheng A.-L; Hsu C.
臺大學術典藏	2020-05-26T09:27:17Z	Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.	Shao Y.Y;Lin C.C;Chih-Hsin Yang; Shao Y.Y; Lin C.C; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:27:17Z	Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions	Shao Y.-Y;Hu F.-C;Liang J.-T;Chiu W.-T;Cheng A.-L;Chih-Hsin Yang; Shao Y.-Y; Hu F.-C; Liang J.-T; Chiu W.-T; Cheng A.-L; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:27:08Z	Survival of patients with small cell lung carcinoma in Taiwan	Lai M.-S.;Chih-Hsin Yang;Kuo R.N.C;Shau W.-Y;Shao Y.-Y;Yang Y.-Y;Lin Z.-Z;Kuo Y.-H; Kuo Y.-H; Lin Z.-Z; Yang Y.-Y; Shao Y.-Y; Shau W.-Y; Kuo R.N.C; CHIH-HSIN YANG; Lai M.-S.
臺大學術典藏	2020-05-26T09:27:06Z	Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy	Chengb A.-L.;Hsu C.-H;Hong R.-L;Chih-Hsin Yang;Chang D.-Y;Shao Y.-Y;Hu F.-C;Hsu C;Lin Z.-Z; Lin Z.-Z; Hsu C; Hu F.-C; Shao Y.-Y; Chang D.-Y; CHIH-HSIN YANG; Hong R.-L; Hsu C.-H; Chengb A.-L.
臺大學術典藏	2020-05-26T09:27:05Z	Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: An East Asian population-based study	Laie M.-S.;Chih-Hsin Yang;Kuo R.N.-C;Yang Y.-Y;Shao Y.-Y;Shau W.-Y;Lin Z.-Z; Lin Z.-Z; Shau W.-Y; Shao Y.-Y; Yang Y.-Y; Kuo R.N.-C; CHIH-HSIN YANG; Laie M.-S.
臺大學術典藏	2020-05-26T09:27:04Z	Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer	Shao Y.-Y;Shau W.-Y;Lin Z.-Z;Chen H.-M;Kuo R;Chih-Hsin Yang;Lai M.-S.; Shao Y.-Y; Shau W.-Y; Lin Z.-Z; Chen H.-M; Kuo R; CHIH-HSIN YANG; Lai M.-S.
臺大學術典藏	2020-05-26T09:27:01Z	Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size	Lin Z.-Z;Shau W.-Y;Hsu C;Shao Y.-Y;Yeh Y.-C;Kuo R.N.-C;Hsu C.-H;Chih-Hsin Yang;Cheng A.-L;Lai M.-S.; Lin Z.-Z; Shau W.-Y; Hsu C; Shao Y.-Y; Yeh Y.-C; Kuo R.N.-C; Hsu C.-H; CHIH-HSIN YANG; Cheng A.-L; Lai M.-S.
臺大學術典藏	2020-05-26T09:26:56Z	Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma	Lai M.-S.;Chih-Hsin Yang;Cheng A.-L;Chen K.-H;Lai C.-L;Kuo R.N;Lin Z.-Z;Shau W.-Y;Chen H.-M;Shao Y.-Y;Liao B.-C; Liao B.-C; Shao Y.-Y; Chen H.-M; Shau W.-Y; Lin Z.-Z; Kuo R.N; Lai C.-L; Chen K.-H; Cheng A.-L; CHIH-HSIN YANG; Lai M.-S.
臺大學術典藏	2020-05-26T09:26:52Z	The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia	Lai M.-S.;Chih-Hsin Yang;Cheng A.-L;Cheng W.-F;Hsu C;Shao Y.-Y;Yang Y.-Y;Lai C.-L;Shau W.-Y;Kuo R;Lin Z.-Z;Kuo H.-Y; Kuo H.-Y; Lin Z.-Z; Kuo R; Shau W.-Y; Lai C.-L; Yang Y.-Y; Shao Y.-Y; Hsu C; Cheng W.-F; Cheng A.-L; CHIH-HSIN YANG; Lai M.-S.
臺大學術典藏	2020-05-26T09:26:51Z	Cytotoxic chemotherapy as first-line therapy for advanced non-small-cell lung cancer in Taiwan: Daily practice	Lai M.-S.;Cheng A.-L;Chiang C.-J;Chen H.-M;Chih-Hsin Yang;Lee H.-S;Liao B.-C;Shao Y.-Y;Liang Y.-H; Liang Y.-H; Shao Y.-Y; Liao B.-C; Lee H.-S; CHIH-HSIN YANG; Chen H.-M; Chiang C.-J; Cheng A.-L; Lai M.-S.
臺大學術典藏	2020-05-25T07:35:28Z	Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.	Shao Y.Y; Chia-Chi Lin; Yang C.H.
臺大學術典藏	2020-05-25T07:35:10Z	A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma	Yang S.-H; Shao Y.-Y; Chia-Chi Lin; Kuo S.-H; Cheng A.-L; Yeh K.-H.
臺大學術典藏	2020-05-25T06:52:03Z	Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin	Cheng A.-L.; Lin C.-H; Chang K.-J; Kuo W.-H; Hsu C; Lee W.-C; Liau J.-Y; Huang C.-S; Shao Y.-Y;Kuo K.-T;Hu F.-C;Yen-Shen Lu;Huang C.-S;Liau J.-Y;Lee W.-C;Hsu C;Kuo W.-H;Chang K.-J;Lin C.-H;Cheng A.-L.; Shao Y.-Y; Kuo K.-T; Hu F.-C; YEN-SHEN LU
臺大學術典藏	2020-05-25T06:51:58Z	The impact of diabetes mellitus on prognosis of early breast cancer in Asia	Lai M.-S.;Cheng A.-L;Kuo R.N.C;Chen H.-M;Yen-Shen Lu;Lin Z.-Z;Shau W.-Y;Shao Y.-Y;Chen W.-W; Chen W.-W; Shao Y.-Y; Shau W.-Y; Lin Z.-Z; YEN-SHEN LU; Chen H.-M; Kuo R.N.C; Cheng A.-L; Lai M.-S.
臺大學術典藏	2020-05-25T06:51:58Z	Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma	Cheng A.-L.;Hsu C.-H;Shen Y.-C;Huang C.-C;Yen-Shen Lu;Hsiao C.-H;Lee K.-D;Hsu C;Lin Z.-Z;Shao Y.-Y; Shao Y.-Y; Lin Z.-Z; Hsu C; Lee K.-D; Hsiao C.-H; YEN-SHEN LU; Huang C.-C; Shen Y.-C; Hsu C.-H; Cheng A.-L.
臺大學術典藏	2020-05-25T06:51:45Z	Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS	Chiu H.-H;Liao H.-W;Shao Y.-Y;Yen-Shen Lu;Lin C.-H;Tsai I.-L;Kuo C.-H.; Chiu H.-H; Liao H.-W; Shao Y.-Y; YEN-SHEN LU; Lin C.-H; Tsai I.-L; Kuo C.-H.
臺大學術典藏	2020-04-28T07:25:28Z	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma	Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L.; Shen Y.-C.; CHIH-HUNG HSU; Chih-Hung Hsu;Shen Y.-C.;Lin Z.-Z.;Chen P.-J.;Shao Y.-Y.;Ding Y.-H.;Hsu C.;Cheng A.-L.
臺大學術典藏	2020-04-28T07:25:27Z	Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma	Shao Y.-Y.;Lin Z.-Z.;Hsu C.;Shen Y.-C.;Chih-Hung Hsu;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; CHIH-HUNG HSU; Cheng A.-L.
臺大學術典藏	2020-04-28T07:25:26Z	Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy	Shao Y.-Y. ;Lu L.-C. ;Cheng A.-L. ;Chih-Hung Hsu; Shao Y.-Y.; Lu L.-C.; Cheng A.-L.; CHIH-HUNG HSU
臺大學術典藏	2020-04-28T07:25:25Z	High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy	Shao Y.-Y. ;Lin Z.-Z. ;Chen T.-J. ;Hsu C. ;Shen Y.-C. ;Chih-Hung Hsu ;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Shen Y.-C.; CHIH-HUNG HSU; Cheng A.-L.
臺大學術典藏	2020-04-28T07:25:20Z	Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy	Shao Y.-Y.;Wu C.-H.;Lu L.-C.;Chan S.-Y.;Ma Y.-Y.;Yen F.-C.;Chih-Hung Hsu;Cheng A.-L.; Shao Y.-Y.; Wu C.-H.; Lu L.-C.; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; CHIH-HUNG HSU; Cheng A.-L.
臺大學術典藏	2020-04-28T07:25:20Z	Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases	Shao Y.-Y.;Ho M.-C.;Cheng A.-L.;Chih-Hung Hsu; Shao Y.-Y.; Ho M.-C.; Cheng A.-L.; CHIH-HUNG HSU
臺大學術典藏	2020-04-28T07:25:20Z	Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy	Lu L.-C.;Shao Y.-Y.;Chan S.-Y.;Chih-Hung Hsu;Cheng A.-L.; Lu L.-C.; Shao Y.-Y.; Chan S.-Y.; CHIH-HUNG HSU; Cheng A.-L.
臺大學術典藏	2020-04-28T07:25:19Z	Clinical activity of metronomic chemotherapy in liver cancers	Shao Y.-Y.;Cheng A.-L.;Chih-Hung Hsu; Shao Y.-Y.; Cheng A.-L.; CHIH-HUNG HSU
臺大學術典藏	2020-04-28T07:25:18Z	Integrated stable isotope labeling by amino acids in cell culture (SILAC) and isobaric tags for relative and absolute quantitation (iTRAQ) quantitative proteomic analysis identifies galectin-1 as a potential biomarker for predicting sorafenib resistance in liver cancer	Chow L.-P.; Feng W.-C.; Ho W.-C.; Tsai M.-H.; Shao Y.-Y.; CHIH-HUNG HSU; Yeh C.-C.; Yeh C.-C.;Chih-Hung Hsu;Shao Y.-Y.;Ho W.-C.;Tsai M.-H.;Feng W.-C.;Chow L.-P.
臺大學術典藏	2020-04-28T07:25:15Z	Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma	Shao Y.-Y.;Liu T.-H.;Lee Y.-H.;Chih-Hung Hsu;Cheng A.-L.; Shao Y.-Y.; Liu T.-H.; Lee Y.-H.; CHIH-HUNG HSU; Cheng A.-L.
臺大學術典藏	2020-04-28T07:25:14Z	National policies fostering hospice care increased hospice utilization and reduced the invasiveness of end-of-life care for cancer patients	Shao Y.-Y.;Hsiue E.H.-C.;Chih-Hung Hsu;Yao C.-A.;Chen H.-M.;Lai M.-S.;Cheng A.-L.; Shao Y.-Y.; Hsiue E.H.-C.; CHIH-HUNG HSU; Yao C.-A.; Chen H.-M.; Lai M.-S.; Cheng A.-L.
臺大學術典藏	2020-04-28T07:25:14Z	Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study	Lu L.-C.;Chen P.-J.;Yeh Y.-C.;Chih-Hung Hsu;Chen H.-M.;Lai M.-S.;Shao Y.-Y.;Cheng A.-L.; Lu L.-C.; Chen P.-J.; Yeh Y.-C.; CHIH-HUNG HSU; Chen H.-M.; Lai M.-S.; Shao Y.-Y.; Cheng A.-L.
臺大學術典藏	2020-04-28T07:25:13Z	High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma	Shao Y.-Y.;Lin H.;Li Y.-S.;Lee Y.-H.;Chen H.-M.;Cheng A.-L.;Chih-Hung Hsu; Shao Y.-Y.; Lin H.; Li Y.-S.; Lee Y.-H.; Chen H.-M.; Cheng A.-L.; CHIH-HUNG HSU
臺大學術典藏	2020-04-28T07:25:13Z	Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy	Shao Y.-Y.; Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Chih-Hung Hsu;Wang M.-J.;Cheng A.-L.;Hsu C.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; CHIH-HUNG HSU; Wang M.-J.; Cheng A.-L.; Hsu C.
臺大學術典藏	2020-04-28T07:25:13Z	Right or left? Side selection for a totally implantable vascular access device: A randomised observational study	Shao Y.-Y.; Hsu M.-C.; Lin W.-Y.;Lin C.-P.;Chih-Hung Hsu;Lee Y.-H.;Lin Y.-T.;Hsu M.-C.;Shao Y.-Y.; Lin W.-Y.; Lin C.-P.; CHIH-HUNG HSU; Lee Y.-H.; Lin Y.-T.
臺大學術典藏	2020-04-28T07:25:11Z	Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure	Liu T.-H.; CHIH-HUNG HSU; Shao Y.-Y.; Liu T.-H.;Chih-Hung Hsu;Shao Y.-Y.
臺大學術典藏	2020-04-28T07:25:08Z	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy	Lin Z.-Z.;Chen B.-B.;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Chih-Hung Hsu;Cheng A.-L.;Lee R.-C.;Chao Y.;Hsu C.; Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; CHIH-HUNG HSU; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C.
臺大學術典藏	2020-04-10T12:51:19Z	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma	Hsu C.-H.;Shen Y.-C.;Lin Z.-Z.;Chen P.-J.;Shao Y.-Y.;Ding Y.-H.;Chiun Hsu;Cheng A.-L.; Hsu C.-H.; Shen Y.-C.; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Chiun Hsu; Cheng A.-L.

显示项目 251-300 / 396 (共8页)
<< < 1 2 3 4 5 6 7 8 > >>
每页显示[10|25|50]项目

	English \| 正體中文 \| 简体中文 \| 总笔数 :0
	造访人次 : 53292582 在线人数 : 1194 教育部委托研究计画计画执行:国立台湾大学图书馆